Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | “Cluster Headache Syndrome - Pipeline Insights, 2015”- A DelveInsight’s ReportDelveInsight, the leading market research and consulting company has added a new report “Cluster Headache Syndrome - Pipeline Insights, 2015” to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight.
By: DelveInsight Business Research · The report gives information of 5+ pipeline drugs with 2+ companies and 3+ Laboratories actively involved in drug development. There are 2 drugs which are in phase III, 1 in phase II/III and 2 in phase II. · Eli Lilly is developing a lead product LY2951742 which is in Phase III. · R&D activities and technologies used along with the pipeline molecules in development. · Therapeutic assessments by molecule types, route of administration, monotherapy and combination products. · Information related to collaborations, in-licensing and out-licensing deals. DelveInsights, Cluster Headache Syndrome - Pipeline Insights, 2015report provides Cluster Headache Syndrome across the globe. Therefore the report on Cluster Headache Syndrome - Pipeline Insights provides information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage. DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License. For more information on Pipeline Insight Reports, email at info@delveInsight.com About Us DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|